We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
(+14%)
Cap. Flow
-$396M
Cap. Flow
% of AUM
-22.17%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenax Therapeutics
TENX
|
+$13.1M |
| 2 |
BPTH
Bio-Path Holdings Inc
BPTH
|
+$10.3M |
| 3 |
Opko Health
OPK
|
+$7.29M |
| 4 |
State Street SPDR S&P Biotech ETF
XBI
|
+$6.72M |
| 5 |
Gilead Sciences
GILD
|
+$6.04M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MannKind Corp
MNKD
|
+$22.4M |
| 2 |
Arbutus Biopharma
ABUS
|
+$9.33M |
| 3 |
MDVN
MEDIVATION, INC.
MDVN
|
+$5.53M |
| 4 |
AEGR
Aegerion Pharmaceuticals
AEGR
|
+$4.82M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$4.69M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 10.45% |
| 2 | Energy | 0.15% |
| 3 | Communication Services | 0% |
| 4 | Materials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Vertex Pharmaceuticals
VRTX
$124B
| $170M | 9.52% |
24,000
-2,661
| -10% | -$211K |
|
|
2
PUT
Teva Pharmaceuticals
TEVA
$36.9B
| $124M | 6.94% |
23,433
+14,928
| +176% | +$690K |
|
3
CALL
Bristol-Myers Squibb
BMY
$130B
| $86.6M | 4.86% |
16,671
+7,178
| +76% | +$382K |
|
|
4
CALL
Teva Pharmaceuticals
TEVA
$36.9B
| $80.3M | 4.5% |
15,192
+14,525
| +2,178% | +$671K |
|
|
5
PUT
Gilead Sciences
GILD
$167B
| $79.1M | 4.44% |
11,166
+4,358
| +64% | +$342K |
|
6
CALL
Acadia Pharmaceuticals
ACAD
$4.45B
| $64.9M | 3.64% |
26,687
-3,176
| -11% | -$80.3K |
|
7
CALL
Biogen
BIIB
$30.4B
| $63.5M | 3.56% |
2,075
+1,172
| +130% | +$372K |
|
|
AGN
8
CALL
DELISTED
Allergan Inc
AGN
| $44.1M | 2.47% |
3,554
-2,035
| -36% | -$248K |
|
|
9
PUT
Vertex Pharmaceuticals
VRTX
$124B
| $41.9M | 2.35% |
5,926
-3,842
| -39% | -$304K |
|
10
PUT
Merck
MRK
$326B
| $39.7M | 2.23% |
+7,330
| New | +$380K |
|
11
PUT
Regeneron Pharmaceuticals
REGN
$72.9B
| $39M | 2.19% |
1,299
+1,289
| +12,890% | +$397K |
|
12
CALL
AbbVie
ABBV
$465B
| $38.7M | 2.17% |
7,535
+7,018
| +1,357% | +$355K |
|
|
13
CALL
Regeneron Pharmaceuticals
REGN
$72.9B
| $36.5M | 2.05% |
1,216
+564
| +87% | +$174K |
|
14
CALL
Apple
AAPL
$4.99T
| $31.1M | 1.74% |
+16,212
| New | +$308K |
|
|
15
PUT
Apple
AAPL
$4.99T
| $31.1M | 1.74% |
+16,212
| New | +$308K |
|
16
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $28.6M | 1.6% |
4,012
-316
| -7% | -$14.4K |
|
|
CELG
17
PUT
DELISTED
Celgene Corp
CELG
| $28.5M | 1.6% |
4,088
+2,792
| +215% | +$221K |
|
18
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $25M | 1.4% |
1,338
| – | – |
|
|
ITMN
19
CALL
DELISTED
INTERMUNE INC
ITMN
| $22.2M | 1.24% |
6,624
+2,432
| +58% | +$54.2K |
|
|
20
PUT
Opko Health
OPK
$1.23B
| $21.6M | 1.21% |
23,227
+13,800
| +146% | +$121K |
|
|
21
CALL
Gilead Sciences
GILD
$167B
| $21.2M | 1.19% |
2,993
+993
| +50% | +$77.9K |
|
|
22
Teva Pharmaceuticals
TEVA
$36.9B
| $19.3M | 1.08% |
364,741
-101,571
| -22% | -$4.69M |
|
|
23
CALL
Opko Health
OPK
$1.23B
| $18.7M | 1.05% |
20,102
+544
| +3% | +$4.77K |
|
|
SGMO
24
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $18.1M | 1.01% |
+10,010
| New | +$193K |
|
|
SGEN
25
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| $16.9M | 0.95% |
+3,711
| New | +$177K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q1 2014 Portfolio in Review
As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.
Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.
- Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
- Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
- Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
- Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
- Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
- Sabby Management opened 107 new positions and closed 92 in Q1 2014.
- Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.
Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.